Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.
Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).
Researchers at the National Cancer Institute (NCI) have developed a gene-expression profiling-based molecular diagnostic assay to diagnose and classify primary mediastinal large B cell lymphoma (PMBCL) from diffuse large B cell lymphoma (DLBCL). The diagnosis can be done using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies. The NCI seeks licensees and/or co-development partners to commercialize this technology.
Researchers at the National Cancer Institute (NCI) identified a biomarker signature of viral infection that correlates with hepatocellular carcinoma (HCC) incidence in at-risk individuals. It has been validated in a longitudinal cohort to detect HCC with high sensitivity and specificity up to 7 years prior to clinical diagnosis. This viral exposure signature can be easily implemented into diagnostic assays for screening of HCC and is available for licensing and/or co-development opportunities.
Somatic mutations can alter the sensitivity of tumors to T-cell mediated immunotherapy. Identifying genes that positively regulate the sensitivity of cancer cells to T-cell mediated clearance is key for effective treatment in cancer patients. Researchers at the National Cancer Institute (NCI) have identified a panel of genes which are useful in predicting a patient’s response to immunotherapy. NCI seeks partners to co-develop or license the technology toward commercialization.
Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ataxia telangiectasia-mutated and Rad3-related (ATR) kinase phosphorylated at threonine 1989. The antibody can be used for pharmacodynamic assays to quantify drug action on the ATR target.
Investigators at the National Cancer Institute discovered a set of biomarkers that can identify patients with early stage lung cancer who are at a high risk of relapse. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy. The NCI seeks parties to license or co-develop the invention.
Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.
Researchers at the NCI have developed immunologically active peptides of NGEP that activate cytotoxic lymphocytes to effectively kill prostate cancer cells. These peptides can be applied to multiple immunotherapy strategies to treat and prevent prostate cancer.
Researchers at the National Cancer Institute (NCI) developed novel groups of cyanine (Cy) based antibody-drug conjugate (ADC) chemical linkers that undergo photolytic cleavage upon irradiation with near-IR light. By using the fluorescent properties of the Cy linker to monitor localization of the ADC, and subsequent near-IR irradiation of cancerous tissue, drug release could be confined to the tumor microenvironment.
Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.
T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. The National Cancer Institute's Surgery Branch seeks interested parties to license or co-develop the use of T cell receptors (TCRs) cloned against the SSX-2 antigen for the treatment of cancer.
NCI Researchers have discovered Interferon-lambda 4 (IFNL4), a protein found through analysis of genomic data. Preliminary studies indicate that this protein may play a role in the clearance of HCV and may be a new target for diagnosing and treating HCV infection. The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in in-licensing or collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV).
The National Cancer Institute seek parties interested in in-licensing and/or collaborative research to develop and commercialize cell labeling, cell tracking, cell trafficking, cell-based therapy, and PET imaging for cancer.
Despite the growing number of biomarkers that are used for diagnosing and treating carcinomas in general, cancers of the thymus are still diagnosed, stratified and treated by a costly combination of histology, surgery and radiological procedures. The lack of qualified biomarkers associated with thymomas and thymic carcinomas has also hampered the development of targeted therapies. The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a prognostic PCR based test for thymic malignancies.